Alphatec (NASDAQ:ATEC) Trading Up 3.9% - What's Next?

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) was up 3.9% during trading on Thursday . The stock traded as high as $9.92 and last traded at $9.91. Approximately 521,116 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 1,971,084 shares. The stock had previously closed at $9.54.

Analysts Set New Price Targets

Several research firms have weighed in on ATEC. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Barclays increased their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. Finally, Piper Sandler raised their price target on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.67.

Remove Ads

Alphatec Price Performance

The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -8.20 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company's fifty day moving average is $10.96 and its two-hundred day moving average is $8.86.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling

In other Alphatec news, COO Scott Lish sold 27,453 shares of the firm's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 337,321 shares of company stock valued at $3,828,060 in the last quarter. Company insiders own 22.80% of the company's stock.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently modified their holdings of the stock. Atria Investments Inc raised its stake in Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company's stock valued at $109,000 after buying an additional 1,460 shares in the last quarter. Jennison Associates LLC bought a new position in Alphatec during the third quarter worth $686,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after purchasing an additional 297,850 shares during the period. Intech Investment Management LLC bought a new stake in Alphatec during the third quarter valued at $189,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Alphatec by 1.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company's stock worth $4,577,000 after purchasing an additional 15,577 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.